GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (LTS:0QNA) » Definitions » Beneish M-Score

Basilea Pharmaceutica (LTS:0QNA) Beneish M-Score : -3.03 (As of May. 15, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Basilea Pharmaceutica Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.03 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Basilea Pharmaceutica's Beneish M-Score or its related term are showing as below:

LTS:0QNA' s Beneish M-Score Range Over the Past 10 Years
Min: -3.03   Med: -1.42   Max: 24.28
Current: -3.03

During the past 13 years, the highest Beneish M-Score of Basilea Pharmaceutica was 24.28. The lowest was -3.03. And the median was -1.42.


Basilea Pharmaceutica Beneish M-Score Historical Data

The historical data trend for Basilea Pharmaceutica's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Beneish M-Score Chart

Basilea Pharmaceutica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.28 -1.89 -0.39 0.88 -3.03

Basilea Pharmaceutica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 - 0.88 - -3.03

Competitive Comparison of Basilea Pharmaceutica's Beneish M-Score

For the Biotechnology subindustry, Basilea Pharmaceutica's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Basilea Pharmaceutica's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Beneish M-Score falls into.



Basilea Pharmaceutica Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Basilea Pharmaceutica for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8804+0.528 * 1.0042+0.404 * 0.029+0.892 * 1.0668+0.115 * 0.6797
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0277+4.679 * -0.021894-0.327 * 0.9088
=-3.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was CHF55.0 Mil.
Revenue was CHF157.6 Mil.
Gross Profit was CHF130.8 Mil.
Total Current Assets was CHF152.1 Mil.
Total Assets was CHF173.3 Mil.
Property, Plant and Equipment(Net PPE) was CHF20.6 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF1.6 Mil.
Selling, General, & Admin. Expense(SGA) was CHF33.8 Mil.
Total Current Liabilities was CHF47.6 Mil.
Long-Term Debt & Capital Lease Obligation was CHF111.1 Mil.
Net Income was CHF10.5 Mil.
Gross Profit was CHF0.0 Mil.
Cash Flow from Operations was CHF14.2 Mil.
Total Receivables was CHF58.6 Mil.
Revenue was CHF147.8 Mil.
Gross Profit was CHF123.2 Mil.
Total Current Assets was CHF175.4 Mil.
Total Assets was CHF220.8 Mil.
Property, Plant and Equipment(Net PPE) was CHF21.6 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF1.1 Mil.
Selling, General, & Admin. Expense(SGA) was CHF30.8 Mil.
Total Current Liabilities was CHF74.9 Mil.
Long-Term Debt & Capital Lease Obligation was CHF147.7 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(54.991 / 157.634) / (58.552 / 147.765)
=0.348852 / 0.396251
=0.8804

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(123.162 / 147.765) / (130.84 / 157.634)
=0.833499 / 0.830024
=1.0042

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (152.145 + 20.6) / 173.289) / (1 - (175.364 + 21.6) / 220.848)
=0.003139 / 0.108147
=0.029

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=157.634 / 147.765
=1.0668

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.097 / (1.097 + 21.6)) / (1.577 / (1.577 + 20.6))
=0.048332 / 0.07111
=0.6797

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(33.783 / 157.634) / (30.815 / 147.765)
=0.214313 / 0.208541
=1.0277

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((111.091 + 47.592) / 173.289) / ((147.683 + 74.85) / 220.848)
=0.915713 / 1.00763
=0.9088

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(10.451 - 0 - 14.245) / 173.289
=-0.021894

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Basilea Pharmaceutica has a M-score of -3.03 suggests that the company is unlikely to be a manipulator.


Basilea Pharmaceutica Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Basilea Pharmaceutica (LTS:0QNA) Business Description

Traded in Other Exchanges
Address
Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (LTS:0QNA) Headlines

No Headlines